DOP84: Colonic CD4+ T cell senescence is implicated in the progression of experimental colitis in aged miceECCO'24 Stockholm 2024
DOP85: An anti-fibrotic role for eosinophils in a DSS colitis RAG-/- and an in vitro co-culture modelECCO'24 Stockholm 2024
DOP86: FOod Additives on the Mucosal barrier study (FOAM): Effect of five emulsifiers on inflammation, intestinal permeability, and the microbiome: preliminary results.ECCO'24 Stockholm 2024
DOP87: Characterization of pathologic fibroblast and macrophage cell populations in colonic Crohn’s Disease with spatial transcriptomics.ECCO'24 Stockholm 2024
DOP88: Lipids drive myofibroblast activation and the epithelial-mesenchymal transition process in Crohn’s Disease.ECCO'24 Stockholm 2024
DOP90: Amphiregulin promotes colitis-associated intestinal fibrosis through activation of PI3K/AKT signaling in Intestinal fibroblastsECCO'24 Stockholm 2024
OP01: PROFILE: a multi-centre, randomised, open-label, biomarker-stratified clinical trial of treatment strategies for patients with newly-diagnosed Crohn’s diseaseECCO'24 Stockholm 2024
OP02: IL23R-CAR-Tregs: creating a therapeutic breakthrough for Crohn’s DiseaseECCO'24 Stockholm 2024
OP04: Endoscopic healing in paediatric IBD perpetuates a persistent signature characterized by pathogenic Th17 cells and tissue-associated molecular and microbial drivers of diseaseECCO'24 Stockholm 2024
OP05: Primary efficacy and safety of mirikizumab in moderate to severe Crohn’s Disease: results of the treat-through VIVID 1 studyECCO'24 Stockholm 2024
OP06: Risankizumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomised Phase 3 COMMAND StudyECCO'24 Stockholm 2024
OP07: Consistent IBD treatment approaches across South Asian and White ethnicities despite phenotypic variations: a study of 33,157 patients using the IBD BioResourceECCO'24 Stockholm 2024
OP08: Multi-ancestry genome-wide association study of inflammatory bowel disease identifies 125 novel loci and directly implicates new genes in disease susceptibilityECCO'24 Stockholm 2024
OP09: Oral ritlecitinib and brepocitinib in patients with moderate to severe active Crohn’s Disease: Data from the PIZZICATO umbrella studyECCO'24 Stockholm 2024
OP10: Efficacy and safety of upadacitinib in patients with moderately to severely active Crohn’s Disease: results from the U-ENDURE long-term extensionECCO'24 Stockholm 2024
OP11: Exploring the potential clinical utility of NUDT15 pharmacogenetic testing in clinical practice: a ‘focused reverse phenotyping’ study in the UK IBD BioresourceECCO'24 Stockholm 2024
OP12: Mirikizumab improves fatigue, bowel urgency, and quality of life in patients with moderately to severely active Crohn’s Disease: Results from a phase 3 clinical trialECCO'24 Stockholm 2024